• News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • FREE newsletter subscription
  • Search
  • Menu Menu
Clinical Laboratory int.
  • Allergies
  • Cardiac
  • Gastrointestinal
  • Hematology
  • Microbiology
  • Microscopy & Imaging
  • Molecular Diagnostics
  • Pathology & Histology
  • Protein Analysis
  • Rapid Tests
  • Therapeutic Drug Monitoring
  • Tumour Markers
  • Urine Analysis

Archive for category: E-News

E-News

Women 16–49 at risk of multiple pollutants

, 26 August 2020/in E-News /by 3wmedia

Nearly 23 percent of American women of childbearing age met or exceeded the median blood levels for all three environmental chemical pollutants — lead, mercury, and PCBs — tracked in an analysis of data on thousands of women by Brown University researchers. All but 17.3 percent of the women aged 16 to 49 were at or above the median blood level for one or more of these chemicals, which are passed to foetuses through the placenta and to babies through breast milk.
The study identified several risk factors associated with a higher likelihood of a median-or-higher ‘body burden’ for two or more of these chemicals.
The three pollutants are of greatest interest because they are pervasive and persistent in the environment and can harm foetal and infant brain development, albeit in different ways, said study lead author Dr. Marcella Thompson. But scientists don’t yet know much about whether co-exposure to these three chemicals is more harmful than exposure to each chemical alone. Most researchers study the health effects of exposure to an individual chemical, not two or three together.
‘Our research documents the prevalence of women who are exposed to all three of these chemicals,’ said Thompson, who began the analysis as a doctoral student at the University of Rhode Island College of Nursing and has continued the research as a postdoctoral research associate for Brown University’s Superfund Research Program with co-author Kim Boekelheide, professor of pathology and laboratory medicine. ‘It points out clearly the need to look at health outcomes for multiple environmental chemical co-exposures.’
Most of the childbearing-age women — 55.8 percent — exceeded the median for two or more of the three pollutants.
Data were collected between 1999 and 2004 from 3,173 women aged 16 to 49 who participated in the Centers for Disease Control and Prevention National Health and Nutrition Examination Survey (NHANES). The survey was designed to represent the national population of 134.5 million women of childbearing age. Because the original study also elicited a wide variety of information on health behaviours, socio-economic and demographic characteristics, Thompson and Boekelheide were able to identify specific risk factors associated with increased odds of having higher blood levels of lead, mercury, and PCBs.
They found several statistically significant risk factors. The most prominent among them was age. As women grew older, their risk of exceeding the median blood level in two or more of these pollutants grew exponentially to the point where women aged 30 to 39 had 12 times greater risk and women aged 40 to 49 had a risk 30 times greater than those women aged 16 to 19.
Thompson said women aged 40 to 49 would be at greatest risk not only because these chemicals accumulate in the body over time, but also because these women were born in the 1950s and 1960s before most environmental protection laws were enacted.
Fish and heavy alcohol consumption also raised the risk of having higher blood levels. Women who ate fish more than once a week during the prior 30 days had 4.5 times the risk of exceeding the median in two or more of these pollutants. Women who drank heavily had a milder but still substantially elevated risk.
Fish, especially top predators like swordfish and albacore tuna, are known to accumulate high levels of mercury and PCBs, Thompson said. However, there is no known reason why they found a statistically higher association between heavy drinking and a higher body burden of pollutants.
One risk factor significantly reduced a woman’s risk of having elevated blood levels of the pollutants, but it was not good news: breastfeeding. Women who had breastfed at least one child for at least a month sometime in their lives had about half the risk of exceeding the median blood level for two or more pollutants. In other words, Thompson said, women pass the pollutants that have accumulated in their bodies to their nursing infants.
Although the study did not measure whether women with higher levels of co-exposure or their children suffered ill health effects, Thompson said, the data still suggest that women should learn about their risks of co-exposure to these chemicals well before they become pregnant. A woman who plans to become pregnant in her 30s or 40s, for example, will have a high relative risk of having higher blood levels of lead, PCBs, and mercury.
‘We carry a history of our environmental exposures throughout our lives,’ Thompson said. Brown University

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:25Women 16–49 at risk of multiple pollutants

For some women, genes may influence pressure to be thin

, 26 August 2020/in E-News /by 3wmedia

Genetics may make some women more vulnerable to the pressure of being thin, a study led by Michigan State University researchers has found.
From size-zero models to airbrushed film stars, thinness is portrayed as equalling beauty across Western culture, and it’s an ideal often cited as a cause of eating disorder symptoms in young women. The researchers focused on the potential psychological impact of women buying into this perceived ideal of thinness, which they call thin-ideal internalisation. Changes in self-perception and behaviour, caused by this idealisation, can lead to body dissatisfaction, a preoccupation with weight and other symptoms of eating disorders.
‘We’re all bombarded daily with messages extoling the virtues of being thin, yet intriguingly only some women develop what we term thin-ideal internalization,’ said Jessica Suisman, lead author on the study and a researcher in MSU’s Department of Psychology. ‘This suggests that genetic factors may make some women more susceptible to this pressure than others.’
To explore the role of genetic factors in whether women ‘buy in’ to the pressure to be thin, the idealisation of thinness was studied in sets of twins. More than 300 female twins from the MSU Twin Registry, ages 12-22, took part in the study. Suisman and colleagues measured how much participants wanted to look like people from movies, TV and magazines. Once the levels of thin idealisation were assessed, identical twins who share 100 percent of their genes were compared with fraternal twins who share 50 percent.
The results show that identical twins have closer levels of thin idealisation than fraternal twins, which suggests a significant role for genetics. Further analysis shows that the heritability of thin idealisation is 43 percent, meaning that almost half of the reason women differ in their idealisation of thinness can be explained by differences in their genetic makeup.
In addition to the role of genes, findings showed that influences of the environment are also important. The results showed that differences between twins’ environments have a greater role in the development of thin ideal internalisation than wider cultural attitudes, which women throughout Western societies are exposed to.
‘We were surprised to find that shared environmental factors, such as exposure to the same media, did not have as big an impact as expected,’ Suisman said. ‘Instead, non-shared factors that make co-twins different from each other had the greatest impact.’
Although the study did not look at specific environmental triggers, non-shared environmental influences typically include experiences that twins do not share with one another. This could include involvement by one twin in a weight-focused sport like dance, one twin being exposed to more media that promotes thinness than the other, or one of the twins having a friendship group that places importance on weight.
‘The take-home message,’ Suisman said, ‘is that the broad cultural risk factors that we thought were most influential in the development of thin-ideal internalisation are not as important as genetic risk and environmental risk factors that are specific and unique to each twin.’ Michigan State University

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:32For some women, genes may influence pressure to be thin

Wayne State research team finds possible clue to progression of MS

, 26 August 2020/in E-News /by 3wmedia

Wayne State University School of Medicine researchers, working with colleagues in Canada, have found that one or more substances produced by a type of immune cell in people with multiple sclerosis (MS) may play a role in the disease’s progression. The finding could lead to new targeted therapies for MS treatment.
B cells, said Robert Lisak, M.D., professor of neurology at Wayne State and lead author of the study, are a subset of lymphocytes (a type of circulating white blood cell) that mature to become plasma cells and produce immunoglobulins, proteins that serve as antibodies. The B cells appear to have other functions, including helping to regulate other lymphocytes, particularly T cells, and helping maintain normal immune function when healthy.
In patients with MS, the B cells appear to attack the brain and spinal cord, possibly because there are substances produced in the nervous system and the meninges — the covering of the brain and spinal cord — that attract them. Once within the meninges or central nervous system, Lisak said, the activated B cells secrete one or more substances that do not seem to be immunoglobulins but that damage oligodendrocytes, the cells that produce a protective substance called myelin.
The B cells appear to be more active in patients with MS, which may explain why they produce these toxic substances and, in part, why they are attracted to the meninges and the nervous system.
The brain, for the most part, can be divided into gray and white areas. Neurons are located in the gray area, and the white parts are where neurons send their axons — similar to electrical cables carrying messages — to communicate with other neurons and bring messages from the brain to the muscles. The white parts of the brain are white because oligodendrocytes make myelin, a cholesterol-rich membrane that coats the axons. The myelin’s function is to insulate the axons, akin to the plastic coating on an electrical cable. In addition, the myelin speeds communication along axons and makes that communication more reliable. When the myelin coating is attacked and degraded, impulses — messages from the brain to other parts of the body — can ‘leak’ and be derailed from their target. Oligodendrocytes also seem to engage in other activities important to nerve cells and their axons.
The researchers took B cells from the blood of seven patients with relapsing-remitting MS and from four healthy patients. They grew the cells in a medium, and after removing the cells from the culture collected material produced by the cells. After adding the material produced by the B cells, including the cells that produce myelin, to the brain cells of animal models, the scientists found significantly more oligodendrocytes from the MS group died when compared to material produced by the B cells from the healthy control group. The team also found differences in other brain cells that interact with oligodendrocytes in the brain.
‘We think this is a very significant finding, particularly for the damage to the cerebral cortex seen in patients with MS, because those areas seem to be damaged by material spreading into the brain from the meninges, which are rich in B cells adjacent to the areas of brain damage,’ Lisak said. Wayne State University

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:42Wayne State research team finds possible clue to progression of MS

Women choose blood test for the detection of fetal trisomy 2

, 26 August 2020/in E-News /by 3wmedia

For many women pregnancy is a happy and exciting time. However, for those who have had  triple test results that indicate a high risk of Downs syndrome, things can become very stressful, not least because of the risks of miscarriage that are associated with chorionic villus sampling and amniocentesis that are required for a definitive answer. Now, however, a non-invasive molecular genetic blood test, the PrenaTest from Lifecodexx, for the detection of fetal trisomy 21 is available at over 150 qualified prenatal practices and clinics in Germany, Austria, Liechtenstein and Switzerland. Close to 1,000 women whose babies were classed at high risk of trisomy 21 have opted for the test, and evaluation of the PrenaTest analyses shows that the vast majority (97 % of the women tested) could be relieved with regard to the presence of trisomy 21 in their unborn child. Only 1.5 % of the analysed blood samples carried fetal trisomy 21, and as far as known, these positive results have been confirmed by amniocentesis. Another 1.5 % of the blood samples could initially not be reported primarily due to a low amount of cell-free fetal DNA. This is a major step forward in achieving fast, accurate, point-of-care testing at what is undoubtedly a worrying time.

http://tinyurl.com/bm4vmjg

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:20Women choose blood test for the detection of fetal trisomy 2

Telltale visible signs of ageing may predict heart disease

, 26 August 2020/in E-News /by 3wmedia

If you look old, your heart may feel old, according to research presented at the American Heart Association’s Scientific Sessions 2012.

In a new study, those who had three to four ageing signs — receding hairline at the temples, baldness at the head’s crown, earlobe crease, or yellow fatty deposits around the eyelid (xanthelasmata) — had a 57 percent increased risk for heart attack and a 39 percent increased risk for heart disease .

‘The visible signs of ageing reflect physiologic or biological age, not chronological age, and are independent of chronological age,’ said Anne Tybjaerg-Hansen, M.D., the study’s senior author and professor of clinical biochemistry at the University of Copenhagen in Denmark.

Researchers analysed 10,885 participants 40 years and older (45 percent women) in the Copenhagen Heart Study. Of these, 7,537 had frontoparietal baldness (receding hairline at the temples), 3,938 had crown top baldness, 3,405 had earlobe crease, and 678 had fatty deposits around the eye.

In 35 years of follow-up, 3,401 participants developed heart disease and 1,708 had a heart attack.

Individually and combined, these signs predicted heart attack and heart disease independent of traditional risk factors. Fatty deposits around the eye were the strongest individual predictor of both heart attack and heart disease.

Heart attack and heart disease risk increased with each additional sign of ageing in all age groups and among men and women. The highest risk was for those in their 70s and those with multiple signs of ageing.

In the study, nurses and laboratory technicians noted the quantity of gray hair, prominence of wrinkles, the type and extent of baldness, the presence of earlobe crease and eyelid deposits.

‘Checking these visible ageing signs should be a routine part of every doctor’s physical examination,’ Tybjaerg-Hansen said. American Heart Association

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:27Telltale visible signs of ageing may predict heart disease

Genetic make-up of children explains how they fight malaria infection

, 26 August 2020/in E-News /by 3wmedia

Researchers from Sainte-Justine University Hospital Center and University of Montreal have identified several novel genes that make some children more efficient than others in the way their immune system responds to malaria infection. This world-first in integrative efforts to track down genes predisposing to specific immune responses to malaria and ultimately to identify the most suitable targets for vaccines or treatments was published by lead author Dr. Youssef Idaghdour and senior author Pr. Philip Awadalla, whose laboratory has been performing world-wide malaria research for the past 13 years.
‘Malaria is a major health problem world-wide, with over 3 billion individuals at risk and hundreds of thousands of deaths annually, a majority of which are African children under the age of 5. Why are some children prone to infection, while others are resistant and efficiently fight the disease? These are the questions we sought to answer with our study’, Idaghdour says.
However, to succeed where many other studies have failed, the team used an approach different from the classic in vitro one, where the genome is analysed using cells grown in a laboratory. Instead, they used an in vivo approach, analysing blood samples of children from the Republic of Benin, West Africa, collected with the help of collaborators in the city of Cotonou and the nearby village of Zinvié. ‘This approach allowed us to identify how the ‘environment’ engages in an arms race to define the clinical course of the disease, in this case the environment being the number of parasites detected in the child’s blood running against the genetic make-up of the infected child’, Idaghdour explains.
‘We used an innovative combination of technologies that assessed both genetic variation among children and the conditions in which their genes are ‘expressed’. By doing so, we increased the power of our analysis by permitting us not only to detect the mutations, but also to capture their effect depending on how they affect genes being turned ‘on’ or ‘off’ in presence of the parasite’, Awadalla explains. ‘Our approach made us successful, where million-dollar studies have failed in the past. There has never been this many genes associated with malaria discovered in one study.’
This major milestone in understanding how the genetic profile affects the ability of children to cope with infection could pave the way to the development of low-cost genetic profiling tests in a not so far future. ‘Accurate diagnosis of the infectious agent is critical for appropriate treatment, of course. However, determining a patient’s genetic predisposition to infection would allow us to be more aggressive in our treatment of patients, whether we are speaking of vaccines or preventive drugs’, Awadalla says. EurekAlert

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:35Genetic make-up of children explains how they fight malaria infection

Discovery in Ghent could improve screening for sudden cardiac death

, 26 August 2020/in E-News /by 3wmedia

​Unfortunately, newspaper articles about young athletes dying suddenly on the field are not unheard of. Such reports fuel discussions about compulsory screening, for example of young footballers, for heart failure. Research by scientists from Ghent (VIB/UGent) and Italy will benefit these screening methods. They have discovered a link between mutations in a certain gene and the heart condition Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC).
ARVC is a hereditary heart condition in which the heart muscle (particularly the right ventricle) is partly replaced by fatty tissue and connective tissue. Cardiac arrhythmias can occur as a result of the changes in the heart muscle. Severe arrhythmias can cause dizziness or even lead to fainting or an acute cardiac arrest (= sudden death). ARVC is a progressive disease that usually presents during the teenage years.
Mutations in various genes have already been linked to ARVC. These are primarily genes that are responsible for the production of proteins in the desmosomes. Desmosomes are structures in the heart that ensure that the heart muscle cells remain connected to each other. Therefore, it was assumed that defects in the desmosomes were the most important factors in developing ARVC.
Together with Italian scientists, Jolanda van Hengel, studied patients with ARVC who did not exhibit mutations in the desmosomal genes. The scientists identified mutations in the CTNNA3 gene in these patients, which codes for the protein αT-catenin – a component of the area composita. The area composita is a structure specifically modified to the heart, where extra strong connections between cardiac muscle cells occur.
The scientists’ findings indicate that there is a link between mutations in the CTNNA3 gene and ARVC. It was demonstrated for the first time that – in addition to desmosomal genes – an area composita gene also plays a role in the development of ARVC. Future genetic screening tests for ARVC should include the CTNNA3 gene as a standard part of the test. This would increase the value of the screening. VIB

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:23Discovery in Ghent could improve screening for sudden cardiac death

Scientists discover gene behind rare disorders

, 26 August 2020/in E-News /by 3wmedia

Scientists at the Montreal Neurological Institute and Hospital – The Neuro, McGill University working with a team at Oxford University have uncovered the genetic defect underlying a group of rare genetic disorders.
Using a new technique that has revolutionised genetic studies, the teams determined that mutations in the RMND1 gene were responsible for severe neurodegenerative disorders, in two infants, ultimately leading to their early death. Although the teams’ investigations dealt with an infant, their discovery also has implications for understanding the causes of later-onset neurological diseases.
The RMND1 gene encodes a protein that is an important component of the machinery in mitochondria which generates the chemical energy that all cells need to function. Mutations in genes affecting mitochondrial function are common causes of neurological and neuromuscular disorders in adults and children. It is estimated that one newborn baby out of 5000 is at risk for developing one of these disorders. Mortality among such cases is very high.
‘Mitochondria are becoming a focus of research because it’s clear they’re involved in neurodegenerative disorders in a fairly big way,’ says Dr. Eric Shoubridge, an internationally recognised specialist on mitochondrial diseases at The Neuro and lead author of the paper published.
‘For instance, we’re finding that dysfunctional mitochondria may be at the heart of adult-onset disorders like Parkinson’s and Alzheimer’s disease.’
Discovery of the mutations in the RMND1 gene involved using whole-exome sequencing at the McGill University and Genome Québec Innovation Centre. This technique allows all of the genes in the body that code for proteins to be sequenced and analysed in a single experiment. At a cost of about $1000, whole-exome sequencing is much more economical than previous techniques in which lists of candidate genes had to be screened in the search for mutations. The technique is poised to change the face of genetic diagnosis, making testing more efficient and available.
‘Parents who have had a child with a mitochondrial disorder and who are hesitating to have another child now have the possibility to know the cause of the disease. With genetic information, they have reproductive options like in vitro fertilisation,’ says Dr. Shoubridge. The discovery of the RMND1 gene’s role sheds light on disorders of mitochondrial energy metabolism, but therapies to alleviate or cure such disorders remain elusive. Dr. Shoubridge is hopeful that the discovery will encourage pharmaceutical interest. ‘Drug companies are starting to be interested in rare diseases and metabolic disorders like this. They’re picking some genes as potential drug candidates.’ EurekAlert

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:30Scientists discover gene behind rare disorders

New ‘traffic light’ test could save lives with earlier diagnosis of liver disease

, 26 August 2020/in E-News /by 3wmedia

A new ‘traffic light’ test devised by Dr Nick Sheron and colleagues at University of Southampton and Southampton General Hospital could be used in primary care to diagnose liver fibrosis and cirrhosis in high risk populations more easily than at present.
Liver disease develops silently without symptoms, and many people have no idea they have liver failure until it is too late – one-third of people admitted to hospital with end-stage liver disease die within the first few months. A simple test available in primary care could diagnose disease much earlier, enabling those at risk to change their behaviour and save lives.
The Southampton Traffic Light (STL) test combines several different tests and clinical markers which are given a score that indicates the patient’s likelihood of developing liver fibrosis and liver cirrhosis.
The result comes in three colours: red means that the patient has liver scarring (fibrosis) and may even have cirrhosis, green means that there is no cirrhosis and the patient is highly unlikely to die from liver disease over the next five years. Amber means there is at least a 50:50 chance of scarring with a significant possibility of death within five years, and patients are advised to stop drinking to avoid further disease and death.
The test was given to over 1,000 patients, and their progress was carefully followed and monitored afterwards, in some cases over several years, to assess the accuracy of the test in predicting whether they developed liver fibrosis or cirrhosis.
The test proved to be accurate in severe liver disease, and while not a substitute for clinical judgement or other liver function tests, can provide GPs with an objective means to accurately assess the potential severity of liver fibrosis in high-risk patients – for example, heavy drinkers, those with type II diabetes, or obese people.
Dr Nick Sheron, lead author and Head of Clinical Hepatology at the University of Southampton, and consultant hepatologist at Southampton General Hospital, said: ‘We are reliant on general practitioners detecting liver disease in the community so they can intervene to prevent serious liver problems developing, but so far we haven’t been able to give them the tools they need to do this. We hope that this type of test for liver scarring may start to change this because the earlier we can detect liver disease, the more liver deaths we should be able to prevent.’ University of Southampton

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:37New ‘traffic light’ test could save lives with earlier diagnosis of liver disease

Hepatitis C treatment’s side effects can now be studied in the lab

, 26 August 2020/in E-News /by 3wmedia

The adverse side effects of certain hepatitis C medications can now be replicated and observed in Petri dishes and test tubes, thanks to a research team led by Craig Cameron, the Paul Berg Professor of Biochemistry and Molecular Biology at Penn State University. ‘The new method not only will help us to understand the recent failures of hepatitis C antiviral drugs in some patients in clinical trials,’ said Cameron. ‘It also could help to identify medications that eliminate all adverse effects.’ The team’s findings may help pave the way toward the development of safer and more-effective treatments for hepatitis C, as well as other pathogens such as SARS and West Nile virus.
First author Jamie Arnold, a research associate in Cameron’s lab at Penn State, explained that the hepatitis C virus (HCV), which affects over 170,000,000 people worldwide, is the leading cause of liver disease and, although antiviral treatments are effective in many patients, they cause serious side effects in others. ‘Many antiviral medications for treating HCV are chemical analogs for the building blocks of RNA that are used to assemble new copies of the virus’s genome, enabling it to replicate,’ he said. ‘These medications are close enough to the virus’s natural building blocks that they get incorporated into the virus’s genome. But they also are different in ways that lead to the virus’s incomplete replication. The problem, however, is that the medication not only mimics the virus’s genetic material, but also the genetic material of the patient. So, while the drug causes damage to the virus, it also may affect the patient’s own healthy tissues.’
A method to reveal these adverse side effects in the safety of a laboratory setting, rather than in clinical trials where patients may be placed at risk, has been developed by the research team, which includes Cameron; Arnold; Suresh Sharma, a research associate in Cameron’s lab; other scientists at Penn State; and researchers from other academic, government, and corporate labs. ‘We have taken anti-HCV medications and, in Petri dishes and test tubes, we have shown that these drugs affect functions within a cell’s mitochondria,’ Cameron explained. ‘The cellular mitochondria — a tiny structure known as ‘the powerhouse of the cell’ that is responsible for making energy known as ATP — is affected by these compounds and is likely a major reason why we see adverse effects.’ Cameron noted that scientists have known for some time that certain individuals have ‘sick’ mitochondria. Such individuals are likely more sensitive to the mitochondrial side effects of antiviral drugs.
‘We know that antiviral drugs, including the ones used to treat HCV, affect even normal, healthy mitochondria by slowing ATP output,’ Arnold added. ‘While a person with normal mitochondria will experience some ATP and mitochondrial effects, a person who is already predisposed to mitochondrial dysfunction will be pushed over the ‘not enough cellular energy’ threshold by the antiviral drug. The person’s mitochondria simply won’t be able to keep up.’
One of the problems with clinical trials, Arnold explained, is that a drug may be shown to be quite effective but, if even a miniscule percentage of patients have side effects, the U.S. Food and Drug Administration is obligated to put the trial on hold or stop the trial altogether. This possibility makes drug companies reluctant to invest money in drug trials after an adverse event has been observed, even when the drugs could still help millions of people. The researchers hope that their methods eventually will become a part of the pre-clinical development process for this class of antiviral drugs. ‘If we can show, in the lab, that a drug will cause side effects, then these compounds will not enter lengthy, expensive clinical trials and cause harm to patients ‘ he said. ‘What’s more, a drug company can invest its money more wisely and carefully in drug research that will produce safe and effective products. Better and more-willing investments by drug companies ultimately will help patients, because resources will be spent developing drugs that not only work, but that are safe for all patients.’ Penn State Univeristy

https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 0 0 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:36:042021-01-08 11:13:25Hepatitis C treatment’s side effects can now be studied in the lab
Page 95 of 231«‹9394959697›»
Bio-Rad - Preparing for a Stress-free QC Audit

Latest issue of Clinical laboratory

March 2026

CLi Cover MRCH 2026
14 April 2026

Evident launches FV5000 confocal and multiphoton microscope

14 April 2026

Complex demands | Clear focus

17 March 2026

Complement assays for turbidimetry and nephelometry: C1q, C1 Inhibitor, C5 and Factor B

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
clinlab logo blackbg 1

Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only

Subscribe now!

Become a reader.

Free subscription